18F-NaF PET Demonstrating Unusual Focal Tracer Activity in the Brain.

A 60-year-old man with enlarged prostate, hypertension, and diabetes was referred for F-NaF PET/CT to evaluate possible metastatic lesions. The patient appeared asymptomatic on the day of the study, without any signs indicating stroke. Patient also had no known history of malignancy or cerebrovascular disease. He had mild elevation of the prostate-specific antigen level, and biopsy of his prostate was not performed. Patient had long-standing history of chronic back pain and abdominal pain. The PET bone scan demonstrated a large area of very intense tracer uptake in the brain. A subsequent brain MRI revealed prior stroke in the same area.

The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation.

OBJECTIVE: To determine the impact of tocilizumab on physical function and quality of life in patients diagnosed with rheumatoid arthritis. METHODS: A systematic literature review was performed to select for trials that could be used to examine the impact of tocilizumab on patients in terms of health-related physical function, quality of life, and quality of sleep. By examining background therapy, disease duration, and remission rates, we were able to determine the impact that a dose of tocilizumab has on various patients. RESULTS: A total of 2617 tocilizumab-treated patients and 1271 controls were available for this study. Tocilizumab improved the Health Assessment Questionnaire Disability Index score statistically in comparison to the controls, with odds ratios from 1.4 to 7.0. Tocilizumab improved the physical function measure substantially more than the minimal clinically important difference (MCID) (5 units) - 8.9 and 9.7 - compared to 4.1 and 5.0 for controls. Seven and nine units of improvement were observed when measuring fatigue in rheumatoid arthritis patients. Using the Epworth Sleepiness Scale, we found that sleep improved (from 7.7 [3.1] to 3.4 [2.2]). CONCLUSION: Tocilizumab improves function and quality of life and decreases fatigue in patients with rheumatoid arthritis.